ํ•™์Šตํ•˜๊ธฐ

์ปค๋ฎค๋‹ˆํ‹ฐ

๊ตฌ์ž…ํ•˜๊ธฐ

๋’ค๋กœ๊ฐ€๊ธฐ
๐Ÿ“’ ๋‚ด๋ถ„๋น„ (new) > ํ˜ธ๋ฅด๋ชฌ ์ƒ๋ฆฌํ•™ > ๋‡Œํ•˜์ˆ˜์ฒด ํ˜ธ๋ฅด๋ชฌ

๐Ÿ“Š [๋„ํ‘œ ์ถ”๊ฐ€ ๊ถŒ์žฅ] Harrison 22e, Table 390-1 (pg.2988): Anterior Pituitary Hormone Expression and Regulation ๋ณด์™„ ์š”์ฒญ๋“œ๋ฆฝ๋‹ˆ๋‹ค

  • ๋ฐ˜์˜๋œ ๋ณด์™„ ์š”์ฒญ

  • by

  • ๋‘๋ฐ”์ด

  • ยท

  • 2026๋…„ 4์›” 16์ผ

.


2๊ฐœ์˜ ์˜๊ฒฌ

๋ฉ”๋””ํ†ก AI

AI ์ž‘์„ฑ

ยท

2026๋…„ 4์›” 16์ผ

์š”์ฒญํ•˜์‹  Harrison 22e, Table 390-1์˜ ํ•ต์‹ฌ ๋‚ด์šฉ์€ ๋‡Œํ•˜์ˆ˜์ฒด ์ „์—ฝ ์„ธํฌ์˜ ๋ถ„ํ™”์— ๊ด€์—ฌํ•˜๋Š” **์ „์‚ฌ์ธ์ž(Transcription factor)**๋ฅผ ๊ธฐ์ค€์œผ๋กœ ์„ธํฌ ๊ณ„ํ†ต(Lineage)์„ ๋ถ„๋ฅ˜ํ•˜๊ณ , ๊ฐ ์„ธํฌ๊ฐ€ ๋ถ„๋น„ํ•˜๋Š” ํ˜ธ๋ฅด๋ชฌ๊ณผ ์‹œ์ƒํ•˜๋ถ€ ์กฐ์ ˆ(์ž๊ทน/์–ต์ œ) ์ธ์ž๋ฅผ ์ฒด๊ณ„ํ™”ํ•œ ๊ฒƒ์ž…๋‹ˆ๋‹ค.

์ œ๊ณตํ•ด์ฃผ์‹  ๊ฐœ๋…์„œ ๋‚ด์šฉ๊ณผ ์ฒจ๋ถ€๋œ ์ด๋ฏธ์ง€๋ฅผ ์ข…ํ•ฉํ•˜์—ฌ, ํ•ด๋‹น ๋„ํ‘œ(Anterior Pituitary Hormone Expression and Regulation)๋ฅผ ์™„๋ฒฝํ•˜๊ฒŒ ๋Œ€์ฒดํ•˜๊ณ  ํ•™์Šตํ•  ์ˆ˜ ์žˆ๋„๋ก ํ‘œ์™€ ํ•ต์‹ฌ ํ•ด์„ค๋กœ ์žฌ๊ตฌ์„ฑํ•ด ๋“œ๋ฆฝ๋‹ˆ๋‹ค.


๐Ÿ“Š [์š”์•ฝ ๋„ํ‘œ] ๋‡Œํ•˜์ˆ˜์ฒด ์ „์—ฝ ํ˜ธ๋ฅด๋ชฌ์˜ ๋ฐœํ˜„ ๋ฐ ์กฐ์ ˆ (Harrison 22e, Table 390-1 ๊ธฐ๋ฐ˜)

์ „์‚ฌ์ธ์ž (Lineage)์„ธํฌ ์ข…๋ฅ˜ (Cell Type)ํ˜ธ๋ฅด๋ชฌ (Hormone)์‹œ์ƒํ•˜๋ถ€ ์ž๊ทน ์ธ์ž (+)์‹œ์ƒํ•˜๋ถ€ ์–ต์ œ ์ธ์ž (-)ํ‘œ์  ๊ธฐ๊ด€ ๋ฐ ์Œ์„ฑ ํ”ผ๋“œ๋ฐฑ ์ธ์ž
Pit-1Somatotroph (~50%)GHGHRH, GhrelinSomatostatin (SRIF)๊ฐ„ (IGF-1)
Pit-1Lactotroph (~20%)PRLTRH, VIP, EstrogenDopamine (๊ฐ€์žฅ ์ค‘์š”)์œ ๋ฐฉ (ํ”ผ๋“œ๋ฐฑ ์—†์Œ)
Pit-1Thyrotroph (~5%)TSHTRHSomatostatin, Dopamine๊ฐ‘์ƒ์„  (T3, T4)
T-PitCorticotroph (~20%)ACTH (POMC)CRH-๋ถ€์‹ ํ”ผ์งˆ (Cortisol)
SF-1, DAX-1Gonadotroph (~10%)LH, FSHGnRH (๋ฐ•๋™์„ฑ ํ•„์ˆ˜)-๋‚œ์†Œ/๊ณ ํ™˜ (Sex steroids, Inhibin)

(โ€ป ํ‘œ์˜ ๋‚ด์šฉ์€ ์ œ๊ณต๋œ ๊ฐœ๋…์„œ์˜ '3. ๋‡Œํ•˜์ˆ˜์ฒด ์ „์—ฝ ํ˜ธ๋ฅด๋ชฌ ๋ฐ ์กฐ์ ˆ'๊ณผ ์ฒจ๋ถ€๋œ '์ด๋ฏธ์ง€ 2: Hypothalamic-Pituitary-Target Organ Axis'์˜ (+) ์ž๊ทน, (-) ์–ต์ œ ๊ฒฝ๋กœ๋ฅผ ์™„๋ฒฝํžˆ ์ผ์น˜์‹œ์ผœ ๊ตฌ์„ฑํ•œ ๊ฒƒ์ž…๋‹ˆ๋‹ค.)


๐Ÿ’ก ์ƒ์„ธ ํ•ด์„ค ๋ฐ ์ˆ˜ํ—˜์  ํฌ์ธํŠธ (Evidence & Explanation)

1. ์ „์‚ฌ์ธ์ž(Transcription Factor)์— ๋”ฐ๋ฅธ ์„ธํฌ ๊ณ„ํ†ต์˜ ์ดํ•ด

  • Pit-1 ๊ณ„ํ†ต์˜ ์ž„์ƒ์  ์˜์˜: GH, PRL, TSH๋Š” ๋ชจ๋‘ Pit-1์ด๋ผ๋Š” ๋™์ผํ•œ ์ „์‚ฌ์ธ์ž์— ์˜ํ•ด ๋ถ„ํ™”๋ฉ๋‹ˆ๋‹ค. ๋”ฐ๋ผ์„œ Pit-1 ์œ ์ „์ž์— ๋Œ์—ฐ๋ณ€์ด๊ฐ€ ๋ฐœ์ƒํ•˜๋ฉด ์ด ์„ธ ๊ฐ€์ง€ ํ˜ธ๋ฅด๋ชฌ์˜ ๋ณตํ•ฉ ๊ฒฐํ•(Combined pituitary hormone deficiency)์ด ๋ฐœ์ƒํ•ฉ๋‹ˆ๋‹ค.
  • T-Pit์€ ACTH๋ฅผ ๋ถ„๋น„ํ•˜๋Š” Corticotroph ๋ถ„ํ™”์—, SF-1๊ณผ DAX-1์€ LH/FSH๋ฅผ ๋ถ„๋น„ํ•˜๋Š” Gonadotroph ๋ถ„ํ™”์— ํ•„์ˆ˜์ ์ž…๋‹ˆ๋‹ค.

2. ์‹œ์ƒํ•˜๋ถ€ ์กฐ์ ˆ ์ธ์ž์˜ ํ•ต์‹ฌ ํŠน์ง• (์‹œํ—˜ ๋นˆ์ถœ ํฌ์ธํŠธ)

  • Prolactin (PRL)๊ณผ Dopamine: ๋‹ค๋ฅธ ๋‡Œํ•˜์ˆ˜์ฒด ํ˜ธ๋ฅด๋ชฌ๋“ค์€ ์ฃผ๋กœ ์‹œ์ƒํ•˜๋ถ€์˜ '์ž๊ทน(+)'์„ ๋ฐ›์ง€๋งŒ, ํ”„๋กœ๋ฝํ‹ด์€ ๊ธฐ๋ณธ์ ์œผ๋กœ ๋„ํŒŒ๋ฏผ์— ์˜ํ•œ **์ง€์†์ ์ธ ์–ต์ œ(Tonic inhibition)**๋ฅผ ๋ฐ›์Šต๋‹ˆ๋‹ค. ์ฒจ๋ถ€๋œ ํ•ด๋ถ€ํ•™ ์ด๋ฏธ์ง€(์ด๋ฏธ์ง€ 1)์˜ Stalk(์ค„๊ธฐ)๊ฐ€ ์†์ƒ๋˜๋ฉด(Stalk section effect) ๋„ํŒŒ๋ฏผ ์ „๋‹ฌ์ด ๋Š๊ฒจ ํ”„๋กœ๋ฝํ‹ด ๋ถ„๋น„๊ฐ€ ์˜คํžˆ๋ ค **์ฆ๊ฐ€(Hyperprolactinemia)**ํ•˜๊ฒŒ ๋ฉ๋‹ˆ๋‹ค.
  • ๊ณตํ†ต ์–ต์ œ ์ธ์ž (Somatostatin & Dopamine): Somatostatin์€ GH๋ฟ๋งŒ ์•„๋‹ˆ๋ผ TSH์˜ ๋ถ„๋น„๋„ ์–ต์ œํ•ฉ๋‹ˆ๋‹ค. Dopamine์€ PRL๋ฟ๋งŒ ์•„๋‹ˆ๋ผ TSH ๋ถ„๋น„๋„ ์–ต์ œํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค.
  • ๊ณตํ†ต ์ž๊ทน ์ธ์ž (TRH): TRH๋Š” TSH๋ฟ๋งŒ ์•„๋‹ˆ๋ผ PRL์˜ ๋ถ„๋น„๋„ ์ž๊ทนํ•ฉ๋‹ˆ๋‹ค. (์˜ˆ: ์›๋ฐœ์„ฑ ๊ฐ‘์ƒ์„ ๊ธฐ๋Šฅ์ €ํ•˜์ฆ์—์„œ TRH๊ฐ€ ์ฆ๊ฐ€ํ•˜๋ฉด ๊ณ ํ”„๋กœ๋ฝํ‹ดํ˜ˆ์ฆ์ด ๋™๋ฐ˜๋  ์ˆ˜ ์žˆ์Œ)

3. ํ˜ธ๋ฅด๋ชฌ ๋ถ„๋น„ ๋ฆฌ๋“ฌ (Physiologic Variation)

  • ๋ฐ•๋™์„ฑ ๋ถ„๋น„ (Pulsatile secretion): ๋‡Œํ•˜์ˆ˜์ฒด ํ˜ธ๋ฅด๋ชฌ์€ ๊ธฐ๋ณธ์ ์œผ๋กœ ๋ฐ•๋™์„ฑ์œผ๋กœ ๋ถ„๋น„๋ฉ๋‹ˆ๋‹ค. ํŠนํžˆ GnRH๋Š” ๋ฐ˜๋“œ์‹œ '๋ฐ•๋™์„ฑ'์œผ๋กœ ๋ถ„๋น„๋˜์–ด์•ผ LH/FSH๋ฅผ ์ž๊ทนํ•  ์ˆ˜ ์žˆ์Šต๋‹ˆ๋‹ค. ์ž„์ƒ์—์„œ GnRH ์ž‘์šฉ์ œ๋ฅผ ์ง€์†์ (Continuous)์œผ๋กœ ํˆฌ์—ฌํ•˜๋ฉด ์ˆ˜์šฉ์ฒด๊ฐ€ ํƒˆ๊ฐ์ž‘(Desensitization)๋˜์–ด ์˜คํžˆ๋ ค ์„ฑํ˜ธ๋ฅด๋ชฌ ๋ถ„๋น„๊ฐ€ ์–ต์ œ๋˜๋Š”๋ฐ, ์ด๋Š” ์ „๋ฆฝ์„ ์•”, ์„ฑ์กฐ์ˆ™์ฆ ์น˜๋ฃŒ์— ์‘์šฉ๋ฉ๋‹ˆ๋‹ค.
  • ์ผ์ฃผ๊ธฐ ๋ฆฌ๋“ฌ (Circadian rhythm): ACTH/Cortisol์€ ์•„์นจ ๊ธฐ์ƒ ์ง์ „(6~8 AM)์— ๊ฐ€์žฅ ๋†’๊ณ  ์ž์ •์— ๊ฐ€์žฅ ๋‚ฎ์œผ๋ฉฐ, GH๋Š” ์ˆ˜๋ฉด ์‹œ์ž‘ ์งํ›„ ๊นŠ์€ ์ˆ˜๋ฉด(Deep sleep) ์‹œ์— ๊ฐ€์žฅ ๋†’๊ฒŒ ๋ถ„๋น„๋ฉ๋‹ˆ๋‹ค.

์ด๋Ÿฌํ•œ ์ „์—ฝ ํ˜ธ๋ฅด๋ชฌ์˜ ์กฐ์ ˆ ๊ธฐ์ „์€ ์ฒจ๋ถ€๋œ ํ•ด๋ถ€ํ•™ ์ด๋ฏธ์ง€์˜ Superior hypophyseal artery์—์„œ ์œ ๋ž˜ํ•œ **๋ฌธ๋งฅ๊ณ„(Portal vessels)**๋ฅผ ํ†ตํ•ด ์‹œ์ƒํ•˜๋ถ€์˜ ์กฐ์ ˆ ํ˜ธ๋ฅด๋ชฌ(CRH, TRH ๋“ฑ)์ด ์ „์—ฝ์œผ๋กœ ์ „๋‹ฌ๋จ์œผ๋กœ์จ ์ด๋ฃจ์–ด์ง‘๋‹ˆ๋‹ค. ๋ฐ˜๋ฉด ํ›„์—ฝ์€ ํ˜ˆ๊ด€์ด ์•„๋‹Œ ์‹œ์ƒํ•˜๋ถ€ ์‹ ๊ฒฝ์„ธํฌ(SON/PVN)์˜ ์ถ•์‚ญ(Axon)์ด ์ง์ ‘ ์—ฐ๊ฒฐ๋˜์–ด ํ˜ธ๋ฅด๋ชฌ(ADH, Oxytocin)์„ ๋ถ„๋น„ํ•œ๋‹ค๋Š” ํ•ด๋ถ€ํ•™์  ์ฐจ์ด์ ๋„ ํ•จ๊ป˜ ์ˆ™์ง€ํ•˜์‹œ๊ธฐ ๋ฐ”๋ž๋‹ˆ๋‹ค.


๋ฉ”๋””ํ†ก ๋‹˜์ด ๋ณด์™„ ์š”์ฒญ์„ ์™„๋ฃŒํ–ˆ์Šต๋‹ˆ๋‹ค ยท 2026๋…„ 5์›” 5์ผ

๋ฉ”๋””ํ†ก

ยท

2026๋…„ 5์›” 5์ผ

๋ง์”€ ๊ฐ์‚ฌํ•ฉ๋‹ˆ๋‹ค. ํ•ด๋‹น ๋‚ด์šฉ์€ ์‹œํ—˜ ์ถœ์ œ ๊ฒฝํ–ฅ์— ๋น„ํ•ด ๋„ˆ๋ฌด ์ง€์—ฝ์ ์ธ ๋‚ด์šฉ์ด๋ผ๊ณ  ํŒ๋‹จํ•˜์—ฌ ์‚ญ์ œ ์ฒ˜๋ฆฌํ•˜์˜€์Šต๋‹ˆ๋‹ค.


์˜๊ฒฌ ๋‚จ๊ธฐ๊ธฐ